期刊文献+

他克莫司与抗真菌药物的联合抗真菌作用与机制 被引量:1

Antifungal effect and mechanism of tacrolimus combined with antifungal agents
原文传递
导出
摘要 侵袭性真菌感染越来越受到关注,特别是耐药真菌感染的治疗已成为困扰临床的棘手问题。非抗真菌药物与抗真菌药物的联合应用是研究热点之一。本文综述非抗真菌药物他克莫司与常用抗真菌药物联合对多种耐药及敏感的念珠菌、隐球菌、曲霉菌、须疮癣菌及马拉色菌的联合抗真菌作用与分子机制。研究表明,协同作用的分子基础与真菌细胞中存在钙调蛋白磷酸酶和受体结合蛋白有关,但不同菌属机制不尽相同。 More attention has been paid to the invasive fungal infection,especially to the resistant fungal infection.Drug combination between non-antifungal and antifungal drugs is one of those hot topics.This article focuses on reviewing the combined antifungal effects and the synergistic molecular mechanisms of the non-antifungal drug tacrolimus and antifungal agents against sensitive or resistance fungi of Candida,Aspergillus,Cryptococcus,Mentagrophytes and Malassezia species.The results reveal that the basis of the combined antifungal effect could relate to calcineurin and FKBFs,but synergistic molecular mechanism is not all the same for different species.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2010年第9期646-649,共4页 Chinese Journal of New Drugs and Clinical Remedies
基金 山东省攻关课题(2006GG2302016 2007GG20002026)
关键词 他克莫司 抗真菌药 药物协同作用 药物疗法 联合 tacrolimus antifungal agents drug synergism drug therapy combination
  • 相关文献

参考文献20

  • 1李爱民,王睿,刘又宁.难治性真菌感染抗真菌药物联合治疗的研究进展[J].中国药物应用与监测,2008,5(1):52-54. 被引量:9
  • 2程元荣,黄捷.抗真菌抗生素和免疫抑制剂[J].中国新药杂志,2005,14(3):268-273. 被引量:4
  • 3STEINBACH WJ, SCHELL WA, BLANKENSHIP JR, et al. In vitro interactions between antifungale and immunosuppressants against A spergillus fumigatus [J]. Antimicrob Agents Chemother, 2004, 48(5) : 1664-1669.
  • 4SUN SJ, LI Y, GUO Q J, et al. In Vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods[J]. Antimicrob Agents Chemothe, 2008, 52 (2) : 409-417.
  • 5UPPULURI P, NETT J, HEITMAN J, et al. Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilrns[J]. Antimicrob Agents Chemother, 2008, 52(3): 1127- 1132.
  • 6KONTOYIANNIS DP, LEWIS RE, ALEXANDER BD, et al. Caleineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with Cryptococcosis[J]. Antimicrob Agents Chemother, 2008, 52 (2) : 735-738.
  • 7OZAWA H, OKABAYASHI K, KANO R, et al. Antifungal activities of the combination of taerolimus and itraeonazole against Trichophyton mentagrophytes[J]. J Vet Med Sci, 2005, 67(6) : 629-630.
  • 8吴本权,唐英春,张扣兴,张天托,朱家馨,谈淑卿.溶葡萄球菌酶对耐甲氧西林金黄色葡萄球菌的体外抗菌活性[J].中国新药与临床杂志,2002,21(12):708-710. 被引量:4
  • 9STEINBACH WJ, SINGH N, MILLER JL, et al. In vitro interactions between antifungals and immunosuppressants against Aspergillumsfumigates isolates from transplant and nontransplant patients[J]. Antimicrob Agents Chemother, 2004, 48(12): 4922-4925.
  • 10MAESAKI S, MARICHAL P, HOSSAIN MA, et al. Synergic effects of tacrolimus and azole antifungal agents against azoleresistant Candida albican strains [J]. J Antimicrob Chemother, 1998, 42(6): 745-753.

二级参考文献67

  • 1程元荣.微生物产生的免疫抑制剂[J].中国抗生素杂志,1996,21(A00):24-35. 被引量:14
  • 2JOHNSON LB, KAUFFMAN CA. Voriconazole: a new triazole antifungal agent [J]. Clin Infect Dis, 2003, 36 (5): 630-637.
  • 3SCOTF LJ, SIMPSON D. Voriconazole : a review of its use in the management of invasive fungal infections [J]. Drugs, 2007, 7 (2) : 269-298.
  • 4HYLAND R, JONES BC, SMITH DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole [J]. Drug Metab Dispos, 2003, 31 (5) : 540-547.
  • 5XIE W, UPPAL H, SAINI SP, et al. Orphan nuclear receptormediated xenobiotic regulation in drug metabolism [J]. Drug Discov Today, 2004, 9 (10) : 442-449.
  • 6FINCH CK, CHRISMAN CR, BACIEWICZ AM, et al. Rifampin and rifabutin drug interactions: an update [J]. Arch Intern Med, 2002, 162(9) : 985-992.
  • 7TANG C, LIN JH, LU AY. Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction? [J]. Drug Metab Dispos, 2005, 33 (5): 603 -613.
  • 8PURKINS L, WOOD N, GHAHRAMANI P, et al. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration [J]. Br J Clin Pharmacol, 2003, 56 Suppl 1: 37-44.
  • 9DONNELLY JP, de PAUW BE. Voriconazole : a new therapeuticagent with an extended spectrum of antifungal activity [J]. Clin Microbiol Infect, 2004, 10 Suppl 1 : 107-117.
  • 10LIU P, FOSTER G, LABADIE RR, et al. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects [J]. Clin Pharmacal, 2008, 48 (1) : 73- 84.

共引文献44

同被引文献10

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部